JW Shinyak Corporation

KOSDAQ:A067290 Voorraadrapport

Marktkapitalisatie: ₩69.5b

JW Shinyak Inkomsten in het verleden

Verleden criteriumcontroles 3/6

JW Shinyak's earnings have been declining at an average annual rate of -47%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 0.4% per year. JW Shinyak's return on equity is 15.4%, and it has net margins of 2.9%.

Belangrijke informatie

-47.0%

Groei van de winst

-46.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie11.3%
Inkomstengroei0.4%
Rendement op eigen vermogen15.4%
Nettomarge2.9%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Unpleasant Surprises Could Be In Store For JW Shinyak Corporation's (KOSDAQ:067290) Shares

Sep 16
Unpleasant Surprises Could Be In Store For JW Shinyak Corporation's (KOSDAQ:067290) Shares

Is JW Shinyak (KOSDAQ:067290) A Risky Investment?

Mar 04
Is JW Shinyak (KOSDAQ:067290) A Risky Investment?

Factors Income Investors Should Consider Before Adding JW Shinyak Corporation (KOSDAQ:067290) To Their Portfolio

Jan 28
Factors Income Investors Should Consider Before Adding JW Shinyak Corporation (KOSDAQ:067290) To Their Portfolio

Don't Race Out To Buy JW Shinyak Corporation (KOSDAQ:067290) Just Because It's Going Ex-Dividend

Dec 24
Don't Race Out To Buy JW Shinyak Corporation (KOSDAQ:067290) Just Because It's Going Ex-Dividend

What Type Of Returns Would JW Shinyak's(KOSDAQ:067290) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Dec 07
What Type Of Returns Would JW Shinyak's(KOSDAQ:067290) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Opbrengsten en kosten

Hoe JW Shinyak geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

KOSDAQ:A067290 Opbrengsten, kosten en inkomsten (KRW Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2497,6732,82534,2402,485
31 Mar 24103,117-36,27936,3162,700
31 Dec 23104,235-37,35737,6702,904
30 Sep 23107,086-36,22338,3472,878
30 Jun 23105,604-37,10438,9502,733
31 Mar 23102,66168438,4202,538
31 Dec 22102,7101,40038,1192,612
30 Sep 22101,5681,71538,0152,262
30 Jun 22101,3002,52836,9352,700
31 Mar 22101,8682,58037,7302,880
31 Dec 21100,96688437,6743,134
30 Sep 2199,208-3,11138,3933,678
30 Jun 21102,190-3,34439,5432,950
31 Mar 21104,121-2,83739,2612,849
31 Dec 20103,803-6,44639,8182,593
30 Sep 20106,035-2,48241,5682,001
30 Jun 20104,066-1,63741,5052,198
31 Mar 20103,546-3,54442,2502,194
31 Dec 19102,5311,44241,8912,233
30 Sep 1999,622-5,22640,8012,155
30 Jun 1995,312-7,54740,1652,168
31 Mar 1991,624-6,29438,9592,113
31 Dec 1891,776-7,50938,9032,172
30 Sep 1884,709-4,99939,1832,316
30 Jun 1883,805-5,43939,2672,333
31 Mar 1879,307-4,85138,7532,102
31 Dec 1776,843-6,07937,4411,785
30 Sep 1778,791-4,08336,8431,433
30 Jun 1778,558-4,11736,4311,374
31 Mar 1782,414-2,98536,4861,535
31 Dec 1683,385-61836,7051,566
30 Sep 1683,370-1,49736,0061,840
30 Jun 1680,930-23835,0421,801
31 Mar 1678,77348734,3791,722
31 Dec 1576,94525634,5441,732
30 Sep 1575,6482,21434,7321,527
30 Jun 1575,4893,23233,5811,738
31 Mar 1574,77654233,6401,913
31 Dec 1473,018-52732,6272,250
30 Sep 1474,7421,03731,3542,399
30 Jun 1473,309-2,57232,0432,310
31 Mar 1471,882-2,57730,8361,791
31 Dec 1370,695-3,06830,2991,910

Kwaliteitswinsten: A067290 has high quality earnings.

Groeiende winstmarge: A067290 became profitable in the past.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: A067290 has become profitable over the past 5 years, growing earnings by -47% per year.

Versnelling van de groei: A067290 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Winst versus industrie: A067290 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).

Rendement op eigen vermogen

Hoge ROE: A067290's Return on Equity (15.4%) is considered low.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y